Stockreport

IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2- Breast Cancer Treatment Landscape | DelveInsight [Yahoo! Finance]

Celcuity Inc.  (CELC) 
Last celcuity inc. earnings: 3/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: celcuity.com/home/investors
PDF Despite facing competition from other CDK4/6 inhibitors like Novartis' KISQALI and Eli Lilly's VERZENIO, IBRANCE maintains a strong position in the metastatic setting. [Read more]